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Rome, Italy, Freiburg, Germany, London, United Kingdom, and Durham, NCBackground: Adenosine deaminase (ADA)–severe combined
immunodeficiency (SCID) is caused by genetic variants that
disrupt the function of ADA. In its early-onset form, it is rapidly
fatal to infants. Delayed or late-onset ADA-SCID is
characterized by insidious progressive immunodeficiency that
leads to permanent organ damage or death. Quantification of
T-cell receptor excision circles (TRECs) or tandem mass
spectrometry (tandem-MS) analysis of dried blood spots (DBSs)
collected at birth can identify newborns with early-onset ADA-
SCID and are used in screening programs. However, it is not
clear whether these analyses can identify newborns who will
have delayed or late-onset ADA-SCID before symptoms appear.
Objective: Weperformedaretrospective study toevaluatewhether
tandem-MS and quantitative TREC analyses of DBSs could
identify newborns who had delayed-onset ADA-SCID later in life.
Methods: We tested stored DBSs collected at birth from 3
patients with delayed-onset ADA-SCID using tandem-MS (PCT
EP2010/070517) to evaluate levels of adenosine and 29-
deoxyadenosine and real-time PCR to quantify TREC levels. We
also analyzed DBSs from 3 newborns with early-onset ADA-
SCID and 2 healthy newborn carriers of ADA deficiency.
Results: The DBSs taken at birth from the 3 patients
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http://dx.doi.org/10.1016/j.jaci.2012.08.054and 19 mmol/L (normal value, <1.5 mmol/L) and 29-
deoxyadenosine levels of 0.7, 2.7, and 2.4 mmol/L (normal value,
<0.07 mmol/L); the mean levels of adenosine and 29-
deoxyadenosine were respectively 12.0- and 27.6-fold higher
than normal values. DBSs taken at birth from all 3 patients with
delayed-onset ADA deficiency had normal TREC levels, but
TRECs were undetectable in blood samples taken from the
same patients at the time of diagnosis.
Conclusion: Tandem-MS but not TREC quantification identifies
newborns with delayed- or late-onset ADA deficiency. (J Allergy
Clin Immunol 2012;nnn:nnn-nnn.)
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Severe combined immunodeficiency (SCID) is a group of rare
diseases characterized by recurrent serious or often fatal infections.1
Characteristics ofSCIDmeet the followingcriteria necessary for this
disease to be included in a neonatal screening program2: high mor-
tality andmorbidity, an ability to be cured if it is recognized early, an
early presymptomatic phase, availability of simple and inexpensive
tests for disease markers, and defined and available treatments.3
SCIDcanbe identifiedbyusingPCRanalysis of driedblood spots
(DBSs) for T-cell receptor excision circles (TRECs).4 This assay has
a rate of indeterminate or false-positive results similar to that of other
newborn screening tests,4,5 although the rate of indeterminate results
is higher among particular subgroups, such as premature infants.4,5
The costs might be too high for routine use in many countries.
Adenosine deaminase (ADA) deficiency is an autosomal reces-
sive disorder in which genetic variants disrupt the activity or
production of ADA. This deficiency disrupts the purine salvage
pathway and also results in an accumulation of deoxyadenosine in
cells, which blocks the development of TandB cells of the immune
system. ADA deficiency accounts for approximately 15% to 20%
of cases of SCID, although this might be an underestimate because
many infants with this disorder die before a diagnosis is made.6,7
Both delayed- and late-onset ADA-SCID are characterized by
progressive immunodeficiency that leads to recurring severe
infections, immune dysregulation, and organ damage associated
with metabolite accumulation.8,9 The incidence of late-onset
ADA deficiency is also likely to be underestimated, even more
than that of early-onset ADA-SCID.8 However, excellent1
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DBS: Dried blood spotSCID: Severe combined immunodeficiencyTandem-MS: Tandem mass spectrometryTREC: T-cell receptor excision circletherapeutic options are available for all forms of ADA deficiency
if diagnosed at an early stage.10,11
We have recently shown that it is possible to identify patients
withADA-SCIDusing tandemmass spectrometry (tandem-MS) on
DBSs collected at birth during routine newborn screening proce-
dures at a lowcost (0.01V per test).12Anexpandednewborn screen-
ing includingmore than 40metabolic diseases is now performed by
using tandem-MS inmany countries in theworld, so thatmillions of
children worldwide are screened each year for those diseases.13 In
the Tuscany region of Italy, ADA-SCIDhas been added to the panel
of diseases forwhich tandem-MSscreens.A pilot population-based
screening program began in 2010 that uses TREC and tandem-MS
analyses to identify newborns with SCID.
We investigated whether analysis of DBSs collected during
newborn screening procedures can identify patients with delayed-
or late-onset ADA deficiency by using TREC analysis, tandem-
MS, or both.METHODS
Patients
Patients 1-3. We retrieved stored DBSs that were collected at birth
from 3 patients (P1-P3) who were given diagnoses of delayed-onset ADA-
SCID when they were 7, 4, and 3 years old, respectively. The patients
presented with upper and lower airway diseases, ranging from recurrent otitis
and pneumonia to toxic alveolitis, since they were 2 years old. DBSs were
analyzed by using tandem-MS and TREC analysis. Patient P1 is described in
the article by Speckmann et al.14
Patient 4. The expanded newborn screening performed in Tuscany
using tandem-MS identified a DBS in which adenosine and 2’deoxyadenosine
were increased. The levels of the 2 metabolites were approximately 50-fold
lower than those found in patients with early-onset ADA-SCID12 but were still
4- and 17-fold greater, respectively, than those of subjects without this disor-
der. TREC levels were normal.
To exclude a false-positive result, after confirmation of the results using the
same DBS, the recall procedure was started, and patient P4 was invited to the
Pediatric Immunology Department (Meyer Hospital, Florence, Italy) for
clinical and biochemical assessment. She was the first child of her parents,
who were not related. The mother had an uneventful pregnancy and delivery,
and patient P4’s birth weight was 3150 g. On her first and second visits to the
Pediatric Immunology Department (5 and 25 days old), patient P4 was in
excellent condition.
P4 was tested for adenosine and 29-deoxyadenosine with tandem-MS
analysis on DBS, whole-blood and urine samples collected at different times
during the first 7 months of life. We analyzed ADA activity, immunoglobulin
levels, lymphocyte subsets and proliferation, and the sequence of the ADA
gene in the patient and her parents. Patient P4 was also assessed for levels
of 29-deoxydenosine nucleotides (dAXP). Activity of the mutated enzyme
expressed in Escherichia coli was evaluated.8Control subjects
On approval of the institutional review board, we performed tandem-MS
and TREC analyses of DBSs collected at birth from 2 newborns who carriedADA variants associated with SCID (siblings of 2 patients with early-onset
ADA-SCID) and 3 patients with early-onset ADA-SCID. Whole-blood sam-
ples from patients with ADA-SCID and their healthy carrier siblings had
been analyzed for ADA activity.Tandem-MS analysis of DBSs and urine samples
Samples were prepared for routine screening tests, as previously
described,15 with the exception of the butylation procedure, which was not
carried out. The method for identifying ADA metabolites in DBSs has been
patented (PCT EP2010/070517) and validated by using 12,000 DBSs from
healthy newborns.12 Normal values of adenosine are less than 1.5 mmol/L,
and 29-deoxyadenosine is not detectable in DBSs collected at birth from new-
borns without ADA deficiency. The method produced no false-positive results
in 50,000 screened newborns, with no difference between full-term or prema-
ture births. Purines were quantified in DBSs after subtracting background
noise, as determined from a blank spot. Adenosine and 29-deoxyadenosine
levels were measured in urine samples by using a validated high-pressure
liquid chromatography tandem-MS method.16Assays for lymphocyte subsets and proliferation,
ADA activity, and dAXP levels
Lymphocyte subsets and proliferation were analyzed by using standard
cytofluorimetric methods. Immunoglobulin levels were evaluated by using
standard immunometric assays. ADA activity was evaluated with 3 different
methods. Method Awas performed on hemolysates of whole-blood samples,
combining the activity detected in red and white cells. Reference values for
method A were as follows: less than 0.3 U/grams of hemoglobin (gHb) for
early-onset ADA-SCID, 0.4 to 0.8 U/gHb for delayed- or late-onset ADA
deficiency (or carriers of ADAvariants associated with disease), and 0.8 to 2.5
U/gHb for control subjects (normal values).Method Bmeasured ADA activity
in extracts of separated erythrocytes or separated white blood cells; this high-
pressure liquid chromatography–based assay was performed as previously de-
scribed.17 Method C was a radiochemical thin-layer chromatographic assay.18
Normal values for ADA activity in erythrocytes and white blood cells are
63.0 6 41.4 and 1197 6 516 nmol/h/mg protein, respectively. Untreated pa-
tients with new diagnoses of early-onset ADA-SCID and those with delayed-
and late-onset ADA-SCID usually have less than 1% of the normal activity of
ADA in red and white blood cells. Patients with partial phenotypes lack or
have very low ADA activity in red blood cells but have 5% to 70% of the nor-
mal level of ADA activity in nucleated cells.8,19,20
Total adenosine and 29-deoxyadenosine nucleotide (AXP and dAXP,
respectively) levels in erythrocytes were measured in patient P4, as previously
described.8 The normal concentration of dAXP is 0.002 nmol/mL packed red
blood cells (erythrocytes). dAXPwas also expressed as the percentage of total
adenosine nucleotides to compare levels of dAXP that were measured at dif-
ferent times or from different patients: % dAXP 5 [dAXP] 3 100/
[AXP1 dAXP]; the normal value is less than 0.2%. dAXP levels in untreated
patients with ADA-SCID vary with phenotype, as previously reported.8TREC analysis
DNAwas extracted from a single 3.2-mm punch of the DBSs by using the
QIAamp DNA Mini kit (Qiagen, Hilden, Germany) and analyzed by using
real-time quantitative PCR for TRECs and b-actin, as previously described.21
TREC levels were normalized per microliter of blood, assuming that the sam-
ple contains approximately 3 mL of whole blood. Calibration curves were
generated by means of 10-fold serial dilution of plasmids that contain
TREC and b-actin sequences. Diagnostic cutoff scores were established at
25 TRECs/mL.
DBSs had been collected at birth during routine newborn screening
procedures and stored. DBSs were collected in the region of birth: Germany
for patient P114 and Italy for patients P2 to P4.When possible, DBSs were also
collected at diagnosis (Tables I and II). Stored DBSs were retrieved, and
TREC and tandem-MS analyses were performed for each patient by using
the same DBS.
TABLE 1. Patients’ features
Age at
diagnosis Phenotype
Quantitative
TREC level
Adenosine
level (mmol/L)
29-Deoxyadenos-
ine level
(mmol/L)
dAXP
concentration
and
percentage*
Enzymatic
Activity
(method)y Mutations
In
DBSs
At
diagnosis
In
DBSs
At
diagnosis
In
DBSs
At
diagnosis
Patients
P1 7 y Delayed
onset
294/mL 0/mL 10.0 Not
available
0.7 Not
available
168 nmol/mL
(7.1%)
at diagnosis
(7th year)
Not available Splice site mutation
c.78011G>A
c.396dupA
P2 4 y Delayed
onset
220/mL 0/mL 25.0 10.3 2.7 0.9 139 nmol/mL
(5.7%) at
diagnosis
(4th year)
Not available Exon 6: V177M (II)§
Exon 10: E319fsX321
P3 3 y Delayed
onset
708/mL 0/mL 19.0 7.5 2.4 0.2 158 nmol/mL
(6.3%) at
diagnosis
(3rd year)
0.88 U/gHb
(A and B on
red cells)
Exon 5: V129M (II)§
Exon 10: S291L (I)§
P4 Birth,
identified by
screening
To be
assigned
720/mL NA 6.9 NA 1.2 NA 76 nmol/mL
(3.3%) at
7th month
of life
0.52 U/gHb (A)
at 5 d old,
3.3% of
normal (B)
4.2% of
normal (C )
at 7 mo old
Exon 2: H15D (I)§
Exon 3:I50T (IV)§
Positive control subjects
P5 4 mo Early
onset
0/mL 0/mL 4.4 Not
available
2.5 Not
available
Not
available
0.20 U/gHb (A) Exon 3: F61fsX87
Exon 11: E337X
P6 2 mo Early
onset
0/mL 0/mL 11.8 Not
available
5.3 Not
available
Not
available
0.26 U/gHb (A) Exon 5: p.R156C
Exon 10:
c.956_960delAAGAG
P7 14 d Early
onset
0/mL 0/mL 8.6 NA 16.2 NA Not
available
0.44 U/gHb (A) Exon 10: T294K
homozygosis
Negative control subjects
Carrier 1 NA NA 460/mL NA 0.51 NA 0.02 NA NA 0.42 U/gHb (A)
Carrier 2 NA NA 654/mL NA 0.33 NA 0.01 NA NA 0.60 U/gHb (A)
Notes: All DBSs were collected at birth during a routine newborn screening procedure. TREC and tandem-MS analysis were performed on the same DBSs. NA, Not applicable.
*% dAXP 5 [dAXP] 3 100/[AXP 1 dAXP].
For method A, reference values are the following less than 0.3 U/gHb for patients with early-onset ADA-SCID, 0.4 to 0.8 U/gHb for patients with delayed- or late-onset disease or
carriers, and 0.8 to 2.5 U/gHb for subjects without disease (control subjects, normal values). For methods B and C, patients with early-, delayed-, or late-onset disease have usually
less than 1% of normal ADA activity in red and white blood cells; ADA enzymatic activity values of 5% to 70% of normal values are present in the partial phenotype.
Speckmann et al.14
§ADA activity group, according to Arredondo-Vega et al.8
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Tandem-MS analysis
Adenosine levels in DBSs from patients with delayed-onset
ADA-SCID (P1-P3) were 10, 25, and 19 mmol/L, respectively
(normal value, <1.5 mmol/L), and levels of 29-deoxyadenosine
were 0.7, 2.7, and 2.4mmol/L (normal value, <0.07mmol/L; Table
I), respectively; the levels were in the same range of those
measured for patient P4 (Fig 1, C). The mean adenosine and 29-
deoxyadenosine levels in patients P1 to P3 were 12.0- and 27.6-
fold higher, respectively, than the mean normal values obtained
in 50,000 non–ADA-deficient newborns. 29-Deoxyadenosine
levels in patients P1 to P3 and patient P4 were lower than those
previously reported by our group for 3 different patients withearly-onset ADA-SCID (P5-P7; 2.5, 5.3, and 16.2 mmol/L),12
although the difference in levels was not statistically significant.
On the other hand, adenosine levels were greater in patients P1
to P3 compared with those seen in patients with early-onset dis-
ease (P5-P7), without reaching statistical significance (Table I).
No difference in the levels of adenosine and 29-deoxyadenosine
was present in the same patient over time (Fig 2).
Tandem-MS analysis of the DBSs collected at birth from
patient P4 revealed high adenosine (6.9 mmol/L) and 29-deoxy-
adenosine (1.2 mmol/L; Fig 1, C) levels; these were 4.6- and
17.1-fold higher, respectively, than the upper limit found in
DBSs from healthy newborns (Fig 1, A) but significantly lower
than those for patients with early-onset ADA-SCID (Fig 1, B).
TABLE II. Results from tests of follow-up analysis of patient P4
Test date
TREC levels
in DBSs
Adenosine
levels in
DBS
(mmol/L)
29-Deoxyadenosine
levels in DBSs
(mmol/L)
dAXP
(dAXP/AXP%)*
Enzymatic
activity in
red cells
Enzymatic activity
in white blood cells
(method) ADA variants
At birth 720/mL 6.9 1.23 – – – Exon 2: encodes H15D
Exon 3: encodes I50T
At 5th day 783/mL 3.8 0.22 – Absent 0.52 U/gHb (A)
At 25th day 628/mL 0.22 0.04 – – –
At 3rd month 694/mL 1.58 0.08 – – –
At 7th month 746/mL 1.54 0.09 76 nmol/mL
(3.3%)
Absent 3.3% of normal (B)
4.2% of normal (C)
*% dAXP 5 [dAXP] 3 100/[AXP 1 dAXP].
Method A was performed on hemolysates of whole blood, combining activities of red and white cells.
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in an analysis performed on the fifth day of life, on a second DBS
(adenosine level, 3.8 mmol/L; 29-deoxyadenosine level, 0.22
mmol/L; Fig 1, C), and on a urine sample (2.19 mmol/mol creati-
nine of adenosine [normal value, <0.33 mmol/mol creatinine] and
3.1 mmol/mol creatinine of 29-deoxyadenosine [normal value,
<0.01 mmol/mol creatinine]). Results from follow-up analyses
are presented in Table II. Adenosine levels were normal and 29-de-
oxyadenosine was undetectable in the DBSs from the 2 healthy
carriers (siblings of patientswith early-onsetADA-SCID,Table I).TREC analysis
Normal TREC levels were found (Table I) in DBSs collected at
birth from patients P1 to P3. TRECswere undetectable in DBSs or
whole blood frompatients P1 to P3 at the time of diagnosis, aswell
as in 3 DBSs collected at birth from patients with early-onset
ADA-SCID. Quantitative real-time PCR analysis demonstrated
normal TREC levels in the first and second DBSs (collected at
birth and on the fifth day of life) from patient P4 (Table II).
TREC levels were normal in the DBSs collected at birth from
the 2 healthy carriers (Table I).Genetic analysis
Results from sequence analysis of the ADA gene in patients P1
to P3, the patients with early-onset ADA-SCID, and patient P4 are
shown in Table I. All variants found in patients P1 to P3 were pre-
viously described.8,9 Patient P4 had 2 missense substitutions in
ADA: a previously described heterozygous substitution of
c.43C>G in exon 2, which results in His15Asp and was associated
with ADA-SCID in the HumanGeneMutation Database,8 and the
heterozygous substitution c.149T>C in exon 3, which results in
Ile50Thr. The latter variant was not detected in 200 Italian sub-
jects without ADA-SCID, excluding the possibility that it is a pol-
ymorphism that is not associated with disease. Patient P4’s
mother and father were found to be heterozygous carriers of the
variants in exons 2 and 3, respectively.
Two sequence homology-based tools (Sort Intolerant from
Tolerant [SIFT] and Polymorphism Phenotype [PolyPhen]) were
used to predict the effects of the nonsynonymous polymorphisms
found in patient P4. SIFT predicted that Ile50Thr in exon 3 would
not be tolerated, and PolyPhen reported that it would disrupt the
ligand-binding site. However, these predictions could be impre-
cise, and therefore the effects of this substitution on the activity ofADAwere further analyzed (see ‘‘Additional characterization of
patient P4’’ section).
ADA activity
The activities of ADA in cells from patients with early- or
delayed-onset disease and negative control subjects are presented
in Table I.Lymphocyte subset, immunoglobulin, and
proliferation levels
Subsets of lymphocytes in blood samples collected from patient
P4 at the first and second follow-up visits were analyzed by using
flow cytometry (to identify CD31, CD41, CD81, CD191,
CD32CD161CD561, CD311, CD45RA, CD45RO, CD62 ligand,
andCD11adim cells). Proliferationwas analyzedwith PHAorCD3/
CD28 and carboxyfluorescein diacetate succinimidyl ester in flow
cytometry. Values were found to be normal. No data were available
for patients P1 toP3at birth, but patient P1hadmild lymphopenia at
2 months of age that remained stable until 7 years of age.14 Patient
P4 had normal serum immunoglobulin levels when shewas 25 days
old, and patient P1 had normal levels during the 5-year follow-up
period from the second year of age to the time of diagnosis.Additional characterization of patient P4
ADA activity. We expressed the ADA variant of patient P4
(Ile50Thr) in E coli by using a previously described method.8 We
found that it had 29.5% of the activity of ADA from healthy sub-
jects. On the basis of data from Arredondo-Vega et al,8 this level
of enzymatic activity placed patient P4 at the upper limit of the
range for activity group IV, which includes variants found in only
children and adultswith a partialADAdeficiency phenotype.How-
ever the half-life of the Ile50Thr variant at 408Cwas about 17min-
utes, whereas ADA from healthy subjects lost less than 2% of its
activity after 2 hours at 408C, indicating that the variant is unstable.
ADA activity in separated red and white blood cells.
The enzymatic activity of ADA in separate red or white blood
cells was determined in 2 different laboratories by using methods
B and C. No enzymatic activity was found in separated red cells
from patient P4, whereas enzymatic activities in white cells were
found to be 3.3% and 4.2% of those of ADA from healthy
subjects, respectively, at the 2 laboratories. Cells from patient P4
were found to have normal purine-nucleoside phosphorylase
activity, tested as an internal control, at each laboratory.
FIG 1. Tandem-MS and TREC analysis results. A-D,Metabolites adenosine and 29-deoxyadenosine as they
appear in a tandem-MS analysis of DBSs from a representative healthy newborn (Fig 1, A), a typical patient
with early-onset ADA-SCID (Fig 1, B), a patient identified during the newborn screening procedure (P4; Fig 1,
C), and a patient with delayed-onset ADA-SCID (P1; Fig 1,D). Adenosine is indicated by red arrows, and 29-de-
oxyadenosine is indicated by blue arrows. In the same DBSs analyzed by using tandem-MS, TRECs were not
detected in patients with early-onset ADAdeficiency, whereas theywere present at normal levels in a patient
with delayed-onset ADA deficiency (P1), a patient found to be deficient in adenosine and 29-deoxyadenosine
in a newborn screening program (P4), and a negative control subject. TREC levels are included in Table I.
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cells of patient P4 were tested simultaneously at 2 different
laboratories in both frozen and thawed cells obtained when
patients were 7 months old. dAXP levels measured at the 2
laboratories were 76 and 82 nmol/mL, respectively, which is at
the low end of the range observed in patients with a late-onset
phenotype.8 However, the dAXP in the red cells from patient P4
accounted for only 3.3% of total adenine nucleotides, a value less
than that usually detected in patients with late-onset disease and
that has been reported only once in a patient with ADA-SCID
at 6 years of age (M. S. Hershfield, personal observation in
>200 patients with ADA deficiency).DISCUSSION
Clinical findings, increased levels of adenosine and 29-deox-
yadenosine, and sequence analysis of ADA led to a diagnosisof delayed-onset ADA deficiency in patients P1 to P3. However,
their metabolic abnormalities (increased levels of adenosine and
29-deoxyadenosine) were already present at birth and could
have been easily identified by using tandem-MS analysis of
DBSs collected in a newborn screening program. Analysis of
the same DBSs for TRECs did not identify any defect. We there-
fore propose that delayed-onset ADA-SCID can be identified in
newborns through screening programs that include tandem-MS
but not by TREC analysis. Further confirmation of these findings
is now ongoing in our laboratories.
P4 was found to have increased adenosine and 29-deoxyaden-
osine levels in a newborn screening program. These findings,
along with sequence analysis of ADA, indicated that the patient
had ADA deficiency, although TREC levels were normal (as
for patients P1-P3). Both the SIFT and PolyPhen software pre-
dicted deleterious effects of the ADA variant carried by patient
P4, which encoded a I50T substitution. However, these software
FIG 2. Tandem-MS analysis of patient P2. A and B,Metabolites adenosine and 29-deoxyadenosine as they
appear in a tandem-MS analysis of DBSs taken at diagnosis (Fig 2, A) or at birth (Fig 2, B) from a patient with
delayed-onset disease (P2). Adenosine is indicated by red arrows, and 29-deoxyadenosine is indicated by
blue arrows.
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levels of adenosine and 29-deoxyadenosine required to cause im-
mune dysfunction are not known. We extensively analyzed pa-
tient P4 to determine her disease phenotype. Red blood cells
from patient P4 were found to have no ADA enzyme activity,
and white blood cells were found to have levels of activity that
were about 3% to 4% of normal values. According to previous
reports,8,18,20 healthy subjects with partial ADA deficiency
have levels of ADA activity in white cells that are 5% to 70%
of those of control subjects, whereas patients with SCID have
levels of ADA activity that are less than 1% to 2% of those of
control subjects.
The ADAvariant carried by patient P4 was expressed in E coli,
and functional analysis demonstrated its enzymatic activity to be
29.5% that of control ADA, placing it in activity group IV.8 Im-
munodeficiency has not been reported in patients carrying
ADAs from activity group IV.8 Nomissensemutations that reduce
enzyme activity have been previously observed in exon 3 of ADA,
the location of patient P4’s I50T substitution. This ADA variant
was found to be unstable, with a half-life of only 17 minutes at
408C. However, most missense variants found in patients with
ADA deficiency are unstable, including those found in patients
with late-onset or partial deficiency.8,19,20,22,23 It is difficult to pre-
dict how ADA instability will affect patient P4, especially in sit-
uations of febrile infections.
To evaluate the in vivo function of ADA, we measured dAXP
concentrations in red cells from patient P4. Levels of greater
than 70 nmol/mL, as confirmed in 2 different laboratories, would
be at the low range found in patients with a late-onset phenotype.8
On the other hand, dAXP accounted for only 3.3% of total ade-
nine nucleotides, indicating a partial form of ADA defi-
ciency.8,22,24-26 Therefore on the basis of ADA activity, dAXPlevels and percentages in patient P4 appear to border between
partial and late-onset ADA deficiency.
Delayed and late-onset forms ofADA-SCIDarewell known, but
these patients have not been identified in the preinfection period.At
present, a diagnosis of delayed- or late-onset ADA deficiency can
only be made when patients present with recurrent infections and
sometimes autoimmunity. Blood cell numbers, immunoglobulin
levels, and lymphocyte proliferation should be measured; recent
thymic emigrants should be assessed; and adenosine metabolites
should be quantified in the routine analysis of patients of any age
with clinical signs of immunologic disorders. However, by the time
a diagnosis is made, patients might already have permanent organ
damage, as for patients P1 to P3.Our study found that patients with
delayed-onset ADA-SCID have normal thymic function at birth
and that thymic involution occurs over time.
We propose that tandem-MS can be used to identify newborns
with not only early-onset12 but also delayed- and probably late-
onset ADA deficiencies. Analysis of ADA metabolites by means
of tandem-MS would have a low cost12 in most laboratories that
already screen newborns by using tandem-MS. Actually, labora-
tories that perform tandem-MS with hydrazine could be able to
also analyze adenosine and 29-deoxyadenosine at no extra cost.
The method could also be used, at no extra cost, in laboratories
that substitute water for hydrazine. Further studies are needed
to determine the correct time to begin therapy in infants found
to have delayed- or late-onset ADA deficiency.
Clinical and biochemical follow-up analyses of patient P4 are
underway. The low percentage of dAXP detected, as well as the
normal adenosine and 29-deoxyadenosine values observed when
patient P4 was 24 days old, might indicate she could remain
immunocompetent formany years and possibly forever. However,
characterization of her ADA activity and metabolic features
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partialADAdeficiency; it is difficult to predictwhether the disease
will progress to a late-onset phenotype. Detection of abnormal
adenosine metabolite levels in newborns identifies patients that
should be followed and monitored for symptoms of ADA-SCID.
We do not have data on the activity of ADA; adenosine, 29-
deoxyadenosine, or dAXP levels; or immune function of patients P1
toP3 for theperiodbetweenbirth anddiagnosis.Thereforewecannot
predict whether normalization of adenosine and 29-deoxyadenosine
levels found in patient P4’s blood after the 25th day of lifewill result
in a symptom-free life or only represent a ‘‘honeymoon’’ period.
Patients P1 to P3 had severe immunodeficiency; their severe
recurrent infections and lung and thymic damage could have been
avoided through early identification with tandem-MS analysis of
DBSs. Once a newborn is identified to have ADA metabolite
abnormalities in a screening program, he or she should undergo
extensive characterization of ADA activity, dAXP levels and
percentages, and immune function to determine the disease
phenotype. The patient should then be followed to determine
when the first symptoms appear, so that treatment can begin
before damage occurs. The actual aims of screening programs are
not to make diagnoses but to identify patients who need further
characterization with specific tests and clinical follow-up.
Most newborn screening programs for SCID are based on
quantitative analysis of TRECs. However, we recommend the
inclusion of tandem-MS analysis of adenosine and 29-deoxya-
denosine, which is inexpensive12 and can identify newborns with
severe and hypomorphic variants of ADA, who might have SCID
later in life. Moreover, tandem-MS can be useful in countries that
cannot afford TREC analysis but are already using tandem-MS to
screen for other metabolic diseases.
Clinical implications: Tandem-MS to measure adenosine and
29-deoxyadenosine levels, but not quantification of TRECs,
can identify newborns with delayed-onset ADA-SCID. Screen-
ing programs that include tandem-MS analysis could identify
newborns with delayed-onset phenotype before symptoms ap-
pear, and therefore they can be treated before they have serious
organ damage and infections.REFERENCES
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